Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Michael Kvasnicka

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
Current Hematologic Malignancy Reports|October 23, 2013
WHO classification of myeloproliferative neoplasms (MPN): A critical updateHans Michael Kvasnicka
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 11, 2019
The differential diagnosis of classical myeloproliferative neoplasms (MPN): the updated WHO criteriaHans Michael Kvasnicka
The Lancet. Haematology|June 13, 2017
How to define treatment failure for JAK inhibitorsHans Michael Kvasnicka
Current Hematologic Malignancy Reports|April 29, 2010
Is it justified to perform a bone marrow biopsy examination in sustained erythrocytosis?Juergen Thiele, Hans Michael Kvasnicka
Haematologica|February 3, 2009
Myelofibrotic transformation in essential thrombocythemiaJuergen Thiele, Hans Michael Kvasnicka
Current Hematologic Malignancy Reports|April 29, 2010
The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosisJuergen Thiele, Hans Michael Kvasnicka
Seminars in Thrombosis and Hemostasis|May 5, 2006
Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disordersJuergen Thiele, Hans Michael Kvasnicka
American Journal of Hematology|October 22, 2009
Prodromal myeloproliferative neoplasms: the 2008 WHO classificationHans Michael Kvasnicka, Juergen Thiele
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|June 26, 2007
Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classificationHans Michael Kvasnicka, Jürgen Thiele
Seminars in Thrombosis and Hemostasis|July 1, 2006
The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra veraHans Michael Kvasnicka, Juergen Thiele
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Current Hematologic Malignancy Reports|October 23, 2013
WHO classification of myeloproliferative neoplasms (MPN): A critical updateHans Michael Kvasnicka
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 11, 2019
The differential diagnosis of classical myeloproliferative neoplasms (MPN): the updated WHO criteriaHans Michael Kvasnicka
The Lancet. Haematology|June 13, 2017
How to define treatment failure for JAK inhibitorsHans Michael Kvasnicka
Current Hematologic Malignancy Reports|April 29, 2010
Is it justified to perform a bone marrow biopsy examination in sustained erythrocytosis?Juergen Thiele, Hans Michael Kvasnicka
Haematologica|February 3, 2009
Myelofibrotic transformation in essential thrombocythemiaJuergen Thiele, Hans Michael Kvasnicka
Current Hematologic Malignancy Reports|April 29, 2010
The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosisJuergen Thiele, Hans Michael Kvasnicka
Seminars in Thrombosis and Hemostasis|May 5, 2006
Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disordersJuergen Thiele, Hans Michael Kvasnicka
American Journal of Hematology|October 22, 2009
Prodromal myeloproliferative neoplasms: the 2008 WHO classificationHans Michael Kvasnicka, Juergen Thiele
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|June 26, 2007
Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classificationHans Michael Kvasnicka, Jürgen Thiele
Seminars in Thrombosis and Hemostasis|July 1, 2006
The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra veraHans Michael Kvasnicka, Juergen Thiele
Pageof 8